Fezolinetant for Hot Flashes: What the Trials Actually Show

Fezolinetant can reduce moderate-to-severe menopausal hot flashes within a week, without supplying estrogen. That is a real therapeutic option for people who cannot use hormone therapy or prefer not to. It is not proof that the drug outperforms hormone therapy, antidepressants, or gabapentin; no head-to-head randomized trial has established that.

The more interesting part is where fezolinetant works. Rather than acting through estrogen receptors, it blocks the neurokinin-3 (NK3) receptor in a hypothalamic circuit linked to temperature regulation. The clinical trials show a statistically significant benefit over placebo. The harder question is how much of that average benefit a given person will feel—and how to weigh a low absolute rate of serious adverse events against a meta-analytic signal that deserves attention.

A non-hormonal drug aimed at the hot-flash circuit

Menopausal vasomotor symptoms—hot flashes and night sweats—appear to arise when estrogen withdrawal changes signaling in KNDy neurons, named for kisspeptin, neurokinin B, and dynorphin. These neurons sit in the hypothalamus and help regulate the thermoneutral zone: the narrow temperature range in which the body does not need to sweat or shiver.

Neurokinin B can stimulate these cells through the NK3 receptor. Blocking that receptor interrupts the feedback loop thought to trigger vasodilation and sweating. A 2023 systematic review by Rahman et al. and a 2024 class-level review describe this pathway and support NK3 antagonism as a plausible treatment target. Plausible biology alone would not be enough, of course. Plenty of pathways have excellent résumés and disappointing drugs. Fezolinetant also has randomized trial data.

What the phase 3 trials found

In SKYLIGHT 1, a randomized, double-blind, placebo-controlled phase 3 trial of 527 participants, researchers tested fezolinetant 30 mg or 45 mg once daily for 12 weeks. The primary endpoints were changes in daily vasomotor-symptom frequency and severity at weeks 4 and 12. At week 12, the 45 mg group had 2.55 fewer daily events than placebo. Both doses improved symptom frequency at weeks 4 and 12 (p<0.001) and severity (p=0.002 to 0.012).

The pooled SKYLIGHT 1 and 2 analysis included 1,022 participants and gives the clearest view of timing. In the 2025 pooled analysis by Shapiro et al., 45 mg reduced daily symptom frequency by an adjusted mean of 1.46 more events than placebo after one week (95% CI, -2.01 to -0.92). At week 4, the placebo-adjusted reductions were 2.07 events per day with 45 mg and 1.87 with 30 mg. At week 12, they were 2.51 events per day with 45 mg (95% CI, -3.20 to -1.82) and 2.39 with 30 mg.

Those are group averages, not a promise that every patient will lose two hot flashes each day. A responder analysis provides a more practical number: at week 12, 58.7% of participants receiving fezolinetant achieved at least a 50% reduction in symptom frequency, versus 36.0% receiving placebo. That is an odds ratio of 2.542 (95% CI, 1.868 to 3.472) and an absolute difference of about 22.7 percentage points. Put plainly, roughly 23 additional people per 100 treated met that response definition beyond what occurred with placebo.

Symptoms remained improved through 52 weeks in SKYLIGHT 4, a randomized, double-blind, placebo-controlled safety trial of 1,831 participants. Its primary focus was endometrial safety, not long-term comparative efficacy, but the study did confirm maintenance of vasomotor-symptom benefit over the year.

Statistically convincing, clinically more complicated

Across six randomized trials involving 3,657 participants, a 2025 meta-analysis by AlBarakat et al. estimated a standardized effect size of -0.56 at week 4 (95% CI, -0.79 to -0.34) and -0.34 at week 12 (95% CI, -0.45 to -0.14). Both confidence intervals exclude no difference, so the pooled evidence supports a real drug effect.

The smaller effect size at week 12 does not prove that the drug stops working. The primary interpretation is that placebo response grows over time, narrowing the difference between groups. The available trials cannot rule out some pharmacologic adaptation, however. The 52-week trial supports persistence of benefit, but it does not settle why the placebo-adjusted effect size shrank between weeks 4 and 12 in the meta-analysis.

There is another reason to avoid treating a statistically significant average as a universal patient-level result. Morga et al. validated an anchor-based within-person threshold of 5.73 to 6.20 fewer events per day as a meaningful change in vasomotor-symptom frequency. The approximately two-event placebo-adjusted difference in the trials equals about 32% to 35% of that threshold. That comparison does not erase the responder benefit: many individuals did improve substantially. It does mean that the mean difference, by itself, falls below the change most participants identified as meaningful within themselves.

Safety: reassuring findings and one signal that should stay visible

SKYLIGHT 4 found no endometrial malignancies across its treatment groups during 52 weeks. The trial used endometrial biopsy endpoints with blinded readings by three pathologists. Precise hyperplasia counts require the full publication; the abstract-level reporting does not provide enough detail to quote them here.

Liver safety also looks reassuring within the controlled trial windows, with limits. In SKYLIGHT 1, liver-enzyme elevations occurred in one placebo participant, two participants receiving 30 mg, and none receiving 45 mg; the cases were transient, asymptomatic, and resolved. A 2025 pooled safety analysis across three phase 3 studies found no Hy's law cases, a combined laboratory pattern that can signal serious drug-induced liver injury.

Yet the AlBarakat meta-analysis reported higher odds of serious adverse events with fezolinetant than with placebo: odds ratio 1.57. The absolute serious-event rate was low, and the category included varied events rather than one confirmed toxic effect. Still, a 57% increase in odds is not a footnote to hide behind reassuring liver findings. It is a reason for an informed prescribing conversation and for post-marketing surveillance, especially because the randomized evidence spans 12 to 52 weeks rather than years of routine use.

What the evidence cannot tell you

Every key SKYLIGHT phase 3 trial was sponsored by Astellas Pharma. Independent meta-analyses improve the statistical synthesis, but they pool the same sponsor-funded primary studies. No independently funded replication of a key trial appears in this evidence base.

The trials also did not collect objective sleep outcomes such as polysomnography, wrist actigraphy, or validated sleep staging. Fezolinetant reduced nighttime vasomotor symptoms, but fewer night sweats do not establish better sleep architecture, sleep efficiency, or total restorative sleep.

Nor can the current evidence rank fezolinetant against systemic hormone therapy, SSRIs or SNRIs, or gabapentin. The available indirect comparison examined fezolinetant against elinzanetant, another NK3 antagonist. Cross-trial comparisons with other drug classes are tempting and unreliable because the trials can differ in participants, baseline symptom burden, endpoints, and placebo response.

The practical verdict

Fezolinetant 45 mg once daily has credible randomized evidence for reducing moderate-to-severe menopausal hot flashes and night sweats without estrogen. Its effect begins quickly for many patients, and trial data support maintenance through 52 weeks. For someone who cannot use hormone therapy, that makes it a legitimate prescription option rather than a wellness-product substitute with a scientific haircut.

Set expectations accurately. The average placebo-adjusted reduction is about two daily symptoms, while about 23 additional people per 100 achieved at least a 50% reduction by week 12. No supplement, diet, or lifestyle intervention in this evidence base has demonstrated NK3-receptor antagonism in human trials. The safety record is encouraging but incomplete: no Hy's law cases appeared in pooled phase 3 data, while the meta-analysis found an odds ratio of 1.57 for serious adverse events. A clinician can help place those findings beside symptom severity, medical history, and the alternatives that have—or have not—been tried.